NCT03793608View on ClinicalTrials.gov

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

February 19, 2021

Study Completion Date

May 12, 2021

Conditions
Peanut Allergy
Interventions
DRUG

Dupilumab

Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)

Trial Locations (9)

10461

Regeneron Investigational Site, The Bronx

11021

Regeneron Investigational Site, Great Neck

33612

Regeneron Investigational Site, Tampa

46202

Regeneron Investigational Site, Indianapolis

48197

Regeneron Investigational Site, Ypsilanti

94305

Regeneron Investigational Site, Mountain View

L8S 1G5

Regeneron Investigational Site, Hamilton

M5G 1X8

Regeneron Investigational Site, Toronto

H3T 1C5

Regeneron Investigational Site, Montreal

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY